A New Immunologic Method for Detection of Occult Breast Cancer.
Abstract
We investigated the incidence of a 90kD subunit containing glycoprotein tumor-associated antigen (TAA)- specific immune complexes (IC) in sera of breast cancer patients and correlated it with other tumor markers - CEA and CAi5-3. Sera were obtained from 106 patients with histopathologically proven breast cancer, and from 107 self-proclaimed healthy females. Serum samples were analyzed for the presence of the 90kD glycoprotein TAA-specific IC by a murine monoclonal antibody, ADl-40F4, based ELISA. The antibody, developed against an autoimmunogenic glycoprotein TAA, recognized an epitope that is different from those recognized by human polyclonal antibodies. IC captured by AD1-40F4 were realized by enzyme conjugated goat anti-human IgG. A positive test corresponded to a normalized ELISA value above 0.410 OD (mean plus 3 SD at 405nm). The incidence of 90kD glycoprotein TAA-specific IC was significantly higher (p<0.05) in breast cancer patients (63%, or 67/106) than in healthy controls (2.8%, or 3/107). Comparison of the glycoprotein TAA-specific IC results in breast cancer patients with evidence of disease with results of CEA and CA 15-3 revealed that the incidence of abnormal values was increased to 91%. Thus, use of the glycoprotein TAA-specific IC marker in conjunction with CEA and/or CA15-3 may prove to be more sensitive than when used alone for immunodiagnosis and immunoprognosis.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 1995
- Accession Number
- ADA303372
Entities
People
- Rishab K. Gupta